| Gaowa Jin,Wenjuan Wang,Shuqin Deng,Caihong Jiang,Xiaojun Bai,Jun Zhao,Feng Chen,Jixiang Hou,Lanzhen Zhao,Hui Li,Ziyu Lu,Lenggaowa Da,Yungaowa Wu,Xiaoyun Ma,Yahan Wu,Jiali Gao,Quanfu Li. Treatment and survival status of patients with EGFR mutation-positive stage IV lung adenocarcinoma: five-year follow-up results in the Ordos Area of Inner Mongolia, China. Oncol Transl Med, 2018, 4: 158-162. |
| Treatment and survival status of patients with EGFR mutation-positive stage IV lung adenocarcinoma: five-year follow-up results in the Ordos Area of Inner Mongolia, China |
| Received:June 16, 2018 Revised:September 10, 2018 |
| View Full Text View/Add Comment Download reader |
| KeyWord:epidermal growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI); minority areas |
| Author Name | Affiliation | E-mail | | Gaowa Jin | Department of Medical Oncology, Ordos Central Hospital | jingaowank@163.com | | Wenjuan Wang | Department of Medical Oncology, Ordos Central Hospital | | | Shuqin Deng | Department of Medical Oncology, Ordos Central Hospital | | | Caihong Jiang | Department of Medical Oncology, Ordos Central Hospital | | | Xiaojun Bai | Department of Medical Oncology, Ordos Central Hospital | | | Jun Zhao | Department of Medical Oncology, Ordos Central Hospital | | | Feng Chen | Department of Medical Oncology, Ordos Central Hospital | | | Jixiang Hou | Department of Medical Oncology, Ordos Central Hospital | | | Lanzhen Zhao | Department of Medical Oncology, Ordos Central Hospital | | | Hui Li | Department of Medical Oncology, Ordos Central Hospital | | | Ziyu Lu | Department of Medical Oncology, Ordos Central Hospital | | | Lenggaowa Da | Department of Medical Oncology, Ordos Central Hospital | | | Yungaowa Wu | Department of Medical Oncology, Ordos Central Hospital | | | Xiaoyun Ma | Department of Medical Oncology, Ordos Central Hospital | | | Yahan Wu | Department of Medical Oncology, Ordos Central Hospital | | | Jiali Gao | Department of Medical Oncology, Ordos Central Hospital | | | Quanfu Li | Department of Medical Oncology, Ordos Central Hospital | 1729259137@qq.com |
|
| Hits: 5722 |
| Download times: 6738 |
| Abstract: |
| Objective We aimed to determine the epidermal growth factor receptor (EGFR) mutation status and
treatment survival of patients with stage IV lung adenocarcinoma living in the Ordos area of Inner Mongolia,
China.
Methods EGFR testing and first-line tyrosine kinase inhibitor (TKI) treatment rates of patients with stage
IV lung adenocarcinoma were analyzed from June 2012 to June 2016. Kaplan-Meier survival curves were
constructed to compare patients who received different treatment strategies and those harboring different
EGFR mutation statuses.
Results EGFR testing and mutation rates were 65.60% and 52.90%, respectively, and improved
continuously from June 2012 to June 2016. Among patients with EGFR mutations, 38.9% had EGFR 19
del, 48.2% had L858R, 4.2% had co-existing mutations in exons 19 and 21, and 8.4% had uncommon
mutations. The median overall survival (OS) was 29.5, 26.5, and 16.0 months for patients receiving both
TKI and chemotherapy, TKI alone, and chemotherapy alone, respectively (P = 0.047). The OS was 26.5
and 30.0 months for patients harboring EGFR 19 del and L858R mutations, respectively (P = 0.096).
Conclusion The high OS rates of stage IV lung adenocarcinoma patients living in the Ordos area may be
attributed to continuous improvements in EGFR testing and first-line TKI treatment rates. In the era of TKIs,
chemotherapy for increasing OS times should be emphasized. |
| Close |
|
|
|